ArticleCureus2026
Thyroid-Stimulating Hormone (TSH)-Secreting Pituitary Tumor Misdiagnosed for 20 Years: Possible Effect of Long-Term Treatment With Thyroid Hormone.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas (TSHomas) are rare causes of central hyperthyroidism. Misdiagnosis may lead to prolonged inappropriate thyroid hormone therapy. I present a 65-year-old woman who was treated with high-dose levothyroxine for 20 years for presumed primary hypothyroidism despite persistently elevated TSH with normal to high free T4 and T3 levels. Central hyperthyroidism was not considered. A 9-11 mm pituitary lesion remained stable for two decades. Biochemical evaluation revealed an elevated alpha-subunit with negative heterophile antibodies, confirming a TSHoma. She underwent transsphenoidal resection; pathology confirmed a plurihormonal PIT-1-positive adenoma. This case challenges the traditional view that TSHomas are uniformly resistant to thyroid hormone feedback. The tumor's long-term radiographic stability during supraphysiologic levothyroxine therapy raises the possibility of partial feedback sensitivity. The absence of measurable growth over two decades could be supportive of this hypothesis. Discordant thyroid function tests should prompt evaluation for central hyperthyroidism. Biological heterogeneity among TSHomas may influence tumor behavior and therapeutic responsiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.